Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
FDA Office of Orphan Products Development National Jewish Health |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00004689 |
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease.
II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection.
III. Determine the safety and tolerance of amithiozone with chronic dosing in these patients.
IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol, kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
Condition | Intervention | Phase |
---|---|---|
Mycobacterium Avium-Intracellulare Infection |
Drug: amithiozone Drug: clarithromycin Drug: ethambutol Drug: rifampin Drug: streptomycin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Efficacy Study |
Estimated Enrollment: | 50 |
Study Start Date: | January 1991 |
PROTOCOL OUTLINE: The is a randomized, open label study. All patients receive a core regimen of clarithromycin and streptomycin. Patients are randomized into two treatment arms. Arm I patients receive rifampin and ethambutol. Arm II patients receive amithiozone.
Patients are followed for one year to detect any relapse or other complications.
Patients not eligible for this randomized study may be entered on a short open label study with amithiozone.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Study ID Numbers: | 199/13311, NJCIRM-HS-750, NJCIRM-FDR000812 |
Study First Received: | February 24, 2000 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004689 History of Changes |
Health Authority: | United States: Federal Government |
bacterial infection immunologic disorders and infectious disorders mycobacterium avium infection mycobacterium infection rare disease |
Bacterial Infections Thioacetazone Rare Diseases Streptomycin Mycobacterium Infections, Atypical Mycobacterium Avium Complex Infection Mycobacterium avium-intracellulare Infection Anti-Bacterial Agents |
Clarithromycin Rifampin Gram-Positive Bacterial Infections Lung Diseases Mycobacterium Infections Ethambutol Antitubercular Agents |
Bacterial Infections Thioacetazone Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Streptomycin Infection Pharmacologic Actions Actinomycetales Infections Mycobacterium Infections, Atypical |
Mycobacterium avium-intracellulare Infection Protein Synthesis Inhibitors Clarithromycin Anti-Bacterial Agents Gram-Positive Bacterial Infections Therapeutic Uses Mycobacterium Infections Ethambutol Antitubercular Agents |